专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060183766A1 Orally bioavailable CCI-779 formulations 审中-公开
标题翻译：口服生物可利用的CCI-779制剂
公开(公告)号：US20060183766A1
公开(公告)日：2006-08-17
申请号：US11352726
申请日：2006-02-13
申请人： Joseph Boni , Muhammad Ashraf , Eric Benjamin
发明人： Joseph Boni , Muhammad Ashraf , Eric Benjamin
IPC分类号： A61K31/4745
CPC分类号： A61K9/2095 , A61K9/146 , A61K9/2027 , A61K31/4745
摘要： A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (Cmax) of 5.4±1.8 ng/mL and an area under the curve (AUC) of about 66±about 22 ng-hr/ml and the sirolimus has a Cmax of 18.7±9.6 ng/mL and an AUC of about 600±about 228 ng-hr/ml, for a 25 mg unit dose of CCI-779. Another CCI-779 oral dosage form is provided which, after oral administration thereof to a subject, the CCI-779 has a Cmax of 5.7±1.7 ng/mL and an AUC of about 60±about 20 ng-hr/ml and the sirolimus has a Cmax of 17.1±8.1 ng/mL and an AUC of about 548±about 187 ng-hr/ml in whole blood, for a 25 mg unit dose of CCI-779. Products containing these oral dosage forms, and methods of use thereof, are also described.
摘要翻译：提供CCI-779口服剂型，其中口服给予受试者后，CCI-779具有5.4±1.8ng / mL的全血峰浓度（C max）和面积在约66±约22ng-hr / ml的曲线（AUC）下，西罗莫司的C max最大值为18.7±9.6ng / mL，AUC为约600±约228ng-hr / ml，用于25mg单位剂量的CCI-779。提供了另一种CCI-779口服剂型，其在口服给予受试者后，CCI-779的C max≥5.7±1.7ng / mL，AUC为约60±20 ng-hr / ml，并且西罗莫司在全血中的C max最大值为17.1±8.1ng / mL，AUC为约548±约187ng-hr / ml，对于25mg单位剂量的CCI-779。还描述了含有这些口服剂型的产品及其使用方法。

2. 发明授权

US07643943B2 Methods for monitoring drug activities in vivo 失效
标题翻译：体内监测药物活性的方法
公开(公告)号：US07643943B2
公开(公告)日：2010-01-05
申请号：US10793032
申请日：2004-03-05
申请人： Michael E. Burczynski , Joseph Boni , Andrew J. Dorner , Natalie C. Twine , Jennifer Stover , William L. Trepicchio , Virginia Fitzpatrick , Fred Immermann
发明人： Michael E. Burczynski , Joseph Boni , Andrew J. Dorner , Natalie C. Twine , Jennifer Stover , William L. Trepicchio , Virginia Fitzpatrick , Fred Immermann
IPC分类号： G01N33/48
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulatable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo.
摘要翻译：可用于监测CCI-779或其他药物体内活动的方法，系统和设备。可以通过本发明鉴定许多药物活性基因。这些基因在外周血单核细胞中的表达谱可由CCI-779或其他药物调节。因此，这些基因可以用作体内检测或监测药物活性的替代标记物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式